//
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation
Clinical epidemiology of heart failure with preserved ejection fraction (HFpEF) in comparatively young hospitalized patients
Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction"
Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators
Cardiac Implantable Electronic Devices in Patients With Left Ventricular Assist Systems
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial
Dapagliflozin for treating chronic heart failure with reduced ejection fraction
Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction